Your browser doesn't support javascript.
loading
Bioactive nanotherapeutic trends to combat triple negative breast cancer.
Chowdhury, Pallabita; Ghosh, Upasana; Samanta, Kamalika; Jaggi, Meena; Chauhan, Subhash C; Yallapu, Murali M.
Afiliación
  • Chowdhury P; Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, USA.
  • Ghosh U; Department of Biomedical Engineering, School of Engineering, Rutgers University, The State University of New Jersey, Piscataway, NJ, 08854, USA.
  • Samanta K; Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, USA.
  • Jaggi M; Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, USA.
  • Chauhan SC; Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, USA.
  • Yallapu MM; South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, USA.
Bioact Mater ; 6(10): 3269-3287, 2021 Oct.
Article en En | MEDLINE | ID: mdl-33778204
The management of aggressive breast cancer, particularly, triple negative breast cancer (TNBC) remains a formidable challenge, despite treatment advancement. Although newer therapies such as atezolizumab, olaparib, and sacituzumab can tackle the breast cancer prognosis and/or progression, but achieved limited survival benefit(s). The current research efforts are aimed to develop and implement strategies for improved bioavailability, targetability, reduce systemic toxicity, and enhance therapeutic outcome of FDA-approved treatment regimen. This review presents various nanoparticle technology mediated delivery of chemotherapeutic agent(s) for breast cancer treatment. This article also documents novel strategies to employ cellular and cell membrane cloaked (biomimetic) nanoparticles for effective clinical translation. These technologies offer a safe and active targeting nanomedicine for effective management of breast cancer, especially TNBC.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Bioact Mater Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Bioact Mater Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: China